Hutchmed shares rise 5% after positive Phase III lung cancer trial results

Recent pharmaceutical trial results have caused significant market movements. Hutchmed shares rose 5% following positive Phase III lung cancer trial outcomes. Similarly, Argenx shares soared after reporting successful Phase 3 results for its blockbuster autoimmune drug Vyvgart in an autoimmune myositis trial. Conversely, AstraZeneca has scrapped its late-stage lung cancer trial due to a data setback. These developments highlight a volatile period for biotech firms as they navigate critical clinical trial milestones and regulatory data.